Gomes C, Trolin G
J Neural Transm. 1982;54(3-4):265-74. doi: 10.1007/BF01254935.
GABA levels of the whole mouse brain were studied after in vivo inhibition of GABA synthesis by 3-mercaptopropionic acid (3-MPA, 100 mg/kg i.p.) and of GABA degradation by aminooxyacetic acid (AOAA, 3.8-60 mg/kg i.v.). The influence of 3-MPA on GABA levels was investigated in brains where postmortal GABA accumulation was allowed to occur and in brains where this phenomenon was avoided by very rapid dissection and homogenization of the brain in acid (within 50 sec after decapitation). The post-mortal GABA increase was blocked by 86% after injection of 3-MPA and 3 min before decapitation. In the group where the postmortal accumulation was avoided by very rapid homogenization of the brain in acid, GABA levels decreased by 15% within 2 min after 3-MPA (mean turnover time = 14 min). From 2 to 4 min the GABA concentration remained stable at this decreased level. GABA accumulation after AOAA was maximal after a dose of 7.5 to 15 mg/kg. i.v. Doses higher than 60 mg/kg always produced convulsions. The phase of most rapid accumulation of GABA after AOAA indicates a mean turnover time of about 10 min. The first rapid phase of accumulation was followed by a slower phase. It is probable that the turnover time of whole mouse brain GABA is approximately 10-14 min. It is also concluded that AOAA in a dose of around 15 mg/kg i.v. hardly can inhibit GAD in vivo in the mouse brain and that this dose, by this route of administration, could be used for studies of GABA synthesis in vivo in the mouse.
通过腹腔注射3-巯基丙酸(3-MPA,100mg/kg)体内抑制GABA合成以及静脉注射氨氧基乙酸(AOAA,3.8 - 60mg/kg)体内抑制GABA降解后,研究了整个小鼠脑内的GABA水平。在允许死后GABA积累的脑以及通过在酸性条件下非常快速地解剖和匀浆脑(断头后50秒内)来避免这种现象的脑中,研究了3-MPA对GABA水平的影响。在断头前3分钟注射3-MPA后,死后GABA增加被阻断了86%。在通过在酸性条件下非常快速地匀浆脑来避免死后积累的组中,3-MPA注射后2分钟内GABA水平下降了15%(平均周转时间 = 14分钟)。从2到4分钟,GABA浓度在这个降低的水平保持稳定。AOAA给药后,剂量为7.5至15mg/kg静脉注射时GABA积累最大。高于60mg/kg的剂量总是会引起惊厥。AOAA给药后GABA积累最快的阶段表明平均周转时间约为10分钟。第一个快速积累阶段之后是一个较慢的阶段。整个小鼠脑内GABA的周转时间可能约为10 - 14分钟。还得出结论,静脉注射约15mg/kg剂量的AOAA几乎不能在体内抑制小鼠脑内的谷氨酸脱羧酶,并且通过这种给药途径,该剂量可用于小鼠体内GABA合成的研究。